Brief: Cognition Therapeutics Announces Development Plans For Oral CT1812 In Geographic Atrophy Secondary to Dry AMD
15/03/2023 11:43
March 15 (Reuters) - Cognition Therapeutics Inc
CGTX.O :
* COGNITION THERAPEUTICS - IND FOR INVESTIGATION OF CT1812
FOR
GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR
DEGENERATION CLEARED BY U.S. FDA
* COGNITION - PLANS TO INITIATE PHASE 2 MAGNIFY TRIAL OF ITS
ORAL
DRUG CANDIDATE, CT1812 IN 2023
Source text for Eikon: ID:nGNX343P3z
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB